Back to Feed
STAT+: Eli Lilly launches program for employers to subsidize cost of obesity drug outside insurance

Eli Lilly is going beyond its efforts to sell its obesity drug Zepbound directly to patients, and is now trying to target employers. Over a year ago, Lilly launched LillyDirect, an online platform that allows patients to buy Zepbound for a cash price of up to $449 a month with...

🔗 Read more: https://www.statnews.com/2026/03/05/eli-lilly-zepbound-employers/?utm_campaign=rss

#News #Health #Software #Medicine #Science
Edited

Comments

No comments yet. Be the first to comment!